FULC Q1 2022 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-45.9% YoY

Gross Profit

-$15M-587.9% margin

Operating Income

-$26M-1003.0% margin

Net Income

-$26M-1000.3% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-48.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$220M

Total Liabilities

$31M

Stockholders' Equity

$189M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$5M	-45.9%
Gross Profit	-$15M	-$12M	-32.0%
Operating Income	-$26M	-$17M	-52.5%
Net Income	-$26M	-$17M	-52.5%